Top

BY Clayton Boldt

Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110 new cases will be diagnosed in 2019, with nearly 13,000 deaths caused by the disease. Certain patients have what is known as high-risk multiple myeloma (HRMM), meaning they have distinct molecular features that lead to more rapid progression and poorer outcomes.

The High-Risk Multiple Myeloma...

Robert Orlowski, M.D., Ph.D., leads a Moon Shot dedicated to finding new, longer-lasting options for patients with high-risk multiple myeloma, including a variety of immunotherapy options.

BY Linda Gilchriest

Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers...

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Scott Merville

Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing fibrosis and blood vessel formation, researchers at The University of Texas MD Anderson Cancer Center and Houston Methodist Cancer Center/Houston Methodist Research Institute report in Clinical Cancer Research.

The team also found that the antibody developed to block the microfibril associated...

Researchers have found that targeting the MFAP5 protein in mouse models reduces the fibrosis involved in ovarian and pancreatic cancers.

BY Scott Merville

MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...

BY Clayton R. Boldt, Ph.D.

The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase...

BY Clayton R. Boldt, Ph.D.

Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...

BY Devon Carter

DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...

BY Kellie Bramlet Blackburn

In recent years, the surgical technique sentinel lymph node biopsy has allowed surgeons to more accurately determine how far cancer has spread...

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...